AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 31652875 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined supplementation with glycine and tryptophan
Number of subjects: 0
Study 31652875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine alone
Number of subjects: 0
Study 31652875 — intervention group
Group type: EXPERIMENTAL
Intervention: Glycine and tryptophan mixture
Number of subjects: 0
Study 31652875 — intervention group
Group type: COMPARATOR
Intervention: Placebo (dextrin)
Number of subjects: 0
Study 29200944 — intervention group
Group type: EXPERIMENTAL
Intervention: Therapeutic cervical medial branch blocks (with or without steroids)
Number of subjects: 120
Study 26091193 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 2.5 mg b.i.d.
Number of subjects: 306
Study 26091193 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine 5 mg b.i.d.
Number of subjects: 306
Study 26091193 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 306
Study 26091193 — intervention group
Group type: EXPERIMENTAL
Intervention: Asenapine (OLE phase)
Number of subjects: 306
Study 24121097 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered cognitive behavioral treatment for insomnia with weekly email support
Number of subjects: 262
Study 24121097 — intervention group
Group type: COMPARATOR
Intervention: Internet-delivered cognitive behavioral treatment for insomnia without support
Number of subjects: 262
Study 22111354 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous remifentanil
Number of subjects: 20
Study 22111354 — intervention group
Group type: COMPARATOR
Intervention: Epidural ropivacaine
Number of subjects: 20
Study 22111354 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 20
Study 19812445 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg maraviroc
Number of subjects: 24
Study 22240547 — intervention group
Group type: EXPERIMENTAL
Intervention: Complex Training (CT)
Number of subjects: 30
Study 22240547 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistance Training (RT)
Number of subjects: 30
Study 22240547 — intervention group
Group type: EXPERIMENTAL
Intervention: Plyometric Training (PT)
Number of subjects: 30
Study 22240547 — intervention group
Group type: COMPARATOR
Intervention: Control (not specified)
Number of subjects: 30
Study 15593395 — intervention group
Group type: COMPARATOR
Intervention: Healthy adult volunteers (HAV)
Number of subjects: 72
Study 15593395 — intervention group
Group type: EXPERIMENTAL
Intervention: Duration of disease
Number of subjects: 72
Study 15593395 — intervention group
Group type: EXPERIMENTAL
Intervention: Biochemical parameters
Number of subjects: 72
Study 12730746 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 211
Study 12730746 — intervention group
Group type: EXPERIMENTAL
Intervention: 1 mg risedronate
Number of subjects: 211
Study 12730746 — intervention group
Group type: EXPERIMENTAL
Intervention: 2.5 mg risedronate
Number of subjects: 211
Study 12730746 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 mg risedronate
Number of subjects: 211
Study 12730746 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (1-5 mg doses)
Number of subjects: 211
Study 12730746 — intervention group
Group type: EXPERIMENTAL
Intervention: Risedronate (up to 5 mg)
Number of subjects: 211
Study 9690751 — intervention group
Group type: EXPERIMENTAL
Intervention: Mono test
Number of subjects: 875
Study 9690751 — intervention group
Group type: EXPERIMENTAL
Intervention: Tine test
Number of subjects: 875
Study 9690751 — intervention group
Group type: COMPARATOR
Intervention: Mantoux test
Number of subjects: 875
Study 8078010 — intervention group
Group type: EXPERIMENTAL
Intervention: Urokinase
Number of subjects: 41
Study 8078010 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 41
Study 2680843 — intervention group
Group type: EXPERIMENTAL
Intervention: RS 86 (cholinergic agent)
Number of subjects: 50
Study 2680843 — intervention group
Group type: COMPARATOR
Intervention: Baseline EEG-sleep parameters
Number of subjects: 50
Study 2680843 — intervention group
Group type: EXPERIMENTAL
Intervention: RS 86
Number of subjects: 50
Study 2680843 — intervention group
Group type: COMPARATOR
Intervention: REM sleep density
Number of subjects: 50
Study 2680843 — intervention group
Group type: COMPARATOR
Intervention: Shortened REM latencies
Number of subjects: 50
Study 607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Gastric bypass
Number of subjects: 38
Study 607594 — intervention group
Group type: EXPERIMENTAL
Intervention: Jejunoileal bypass
Number of subjects: 38
Study 29281749 — intervention group
Group type: EXPERIMENTAL
Intervention: Mother-Infant Psychoanalysis (MIP)
Number of subjects: 33
Study 29281749 — intervention group
Group type: COMPARATOR
Intervention: Child Health Center care
Number of subjects: 33
Study 27737690 — intervention group
Group type: COMPARATOR
Intervention: Conventional lung‐protective MV
Number of subjects: 306
Study 27737690 — intervention group
Group type: EXPERIMENTAL
Intervention: Conventional lung‐protective MV with NAVA
Number of subjects: 306
Study 25331469 — intervention group
Group type: EXPERIMENTAL
Intervention: Ropivacaine local infiltration (0.5% ropivacaine, 40 ml, n = 22)
Number of subjects: 61
Study 25331469 — intervention group
Group type: EXPERIMENTAL
Intervention: Sodium chloride local infiltration (0.9% sodium chloride, 40 ml, n = 20)
Number of subjects: 61
Study 25331469 — intervention group
Group type: COMPARATOR
Intervention: Control group (no analgesic, n = 19)
Number of subjects: 61
Study 22779759 — intervention group
Group type: EXPERIMENTAL
Intervention: 6 minute walk test (6MWT)
Number of subjects: 97
Study 20006356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative graft patency assessment using indocyanine‐green fluorescent angiography and transit‐time flowmetry (imaging group)
Number of subjects: 156
Study 20006356 — intervention group
Group type: COMPARATOR
Intervention: Standard intraoperative management (control group)
Number of subjects: 156
Study 20006356 — intervention group
Group type: EXPERIMENTAL
Intervention: Intraoperative graft patency assessment (imaging group)
Number of subjects: 156
Study 18166349 — intervention group
Group type: EXPERIMENTAL
Intervention: Elective gynecological surgery
Number of subjects: 132
Study 18166349 — intervention group
Group type: COMPARATOR
Intervention: Non-surgery controls
Number of subjects: 132
Study 16463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Acetazolamide (ACZ) administration
Number of subjects: 12
Study 16463847 — intervention group
Group type: EXPERIMENTAL
Intervention: Transcranial HPI
Number of subjects: 12
Study 16463847 — intervention group
Group type: COMPARATOR
Intervention: Doppler sonography (TCD)
Number of subjects: 12
Study 12750536 — intervention group
Group type: EXPERIMENTAL
Intervention: Undernourished patients
Number of subjects: 3012
Study 12750536 — intervention group
Group type: COMPARATOR
Intervention: Normal nutritional status
Number of subjects: 3012
Study 10343261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine (0.4 microgram/kg bolus plus 0.1 microgram/kg infusion over 6 hours, n = 81)
Number of subjects: 170
Study 10343261 — intervention group
Group type: COMPARATOR
Intervention: Placebo (n = 89)
Number of subjects: 170
Study 10343261 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous triiodothyronine
Number of subjects: 170
Study 10343261 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 170
Study 7594443 — intervention group
Group type: EXPERIMENTAL
Intervention: Nifedipine (10 mg capsule)
Number of subjects: 20
Study 7594443 — intervention group
Group type: COMPARATOR
Intervention: Dihydralazine (intravenous infusion at a rate of 1-3 mg/h)
Number of subjects: 20
Study 1903023 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation and hyperthermia (42.5 degrees C, 45‐60 min)
Number of subjects: 307
Study 1903023 — intervention group
Group type: COMPARATOR
Intervention: Irradiation alone
Number of subjects: 307
Study 1903023 — intervention group
Group type: EXPERIMENTAL
Intervention: Irradiation and hyperthermia
Number of subjects: 307
Study 6444323 — intervention group
Group type: EXPERIMENTAL
Intervention: 13cis-retinoic acid
Number of subjects: 238
Study 30739485 — intervention group
Group type: EXPERIMENTAL
Intervention: High self-esteem
Number of subjects: 294
Study 30739485 — intervention group
Group type: EXPERIMENTAL
Intervention: Longer duration of care
Number of subjects: 294
Study 30739485 — intervention group
Group type: EXPERIMENTAL
Intervention: Less emotional distress
Number of subjects: 294
Study 30739485 — intervention group
Group type: EXPERIMENTAL
Intervention: Shorter duration of care
Number of subjects: 294
Study 30870236 — intervention group
Group type: EXPERIMENTAL
Intervention: Venlafaxine extended release
Number of subjects: 1573
Study 30870236 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1573
Study 28586878 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary intake of at least 500 mg/d of long-chain omega-3 polyunsaturated fatty acids (LCω3PUFAs)
Number of subjects: 3482
Study 28586878 — intervention group
Group type: EXPERIMENTAL
Intervention: Yearly updated LCω3PUFA intake
Number of subjects: 3482
Study 25698759 — intervention group
Group type: EXPERIMENTAL
Intervention: Alcohol intoxication (0.75 g/kg)
Number of subjects: 48
Study 25698759 — intervention group
Group type: COMPARATOR
Intervention: Placebo (no alcohol)
Number of subjects: 48
Study 25698759 — intervention group
Group type: EXPERIMENTAL
Intervention: Video stimulation (VS)
Number of subjects: 48
Study 23345623 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR therapy (40 min, three times weekly for one year)
Number of subjects: 280
Study 23345623 — intervention group
Group type: COMPARATOR
Intervention: Control group (no FIR therapy)
Number of subjects: 280
Study 23345623 — intervention group
Group type: EXPERIMENTAL
Intervention: FIR therapy
Number of subjects: 280
Study 20395948 — intervention group
Group type: EXPERIMENTAL
Intervention: LAUNCH (6-month clinic and home-based behavioral intervention)
Number of subjects: 18
Study 20395948 — intervention group
Group type: COMPARATOR
Intervention: PC (enhanced standard of care)
Number of subjects: 18
Study 18663500 — intervention group
Group type: EXPERIMENTAL
Intervention: moxifloxacin 400 mg i.v. once daily
Number of subjects: 21
Study 18663500 — intervention group
Group type: COMPARATOR
Intervention: amoxicillin/clavulanic acid 2.2 g i.v. three times daily
Number of subjects: 21
Study 18663500 — intervention group
Group type: COMPARATOR
Intervention: moxifloxacin and amoxicillin/clavulanic acid
Number of subjects: 21
Study 17227570 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg/mL IDN-6556 (Organ storage/flush)
Number of subjects: 0
Study 17227570 — intervention group
Group type: EXPERIMENTAL
Intervention: 5 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Number of subjects: 0
Study 17227570 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 microg/mL IDN-6556 (Organ storage/flush) + 0.5 mg/kg (Recipient)
Number of subjects: 0
Study 17227570 — intervention group
Group type: COMPARATOR
Intervention: Placebo (Organ storage/flush) + Placebo (Recipient)
Number of subjects: 0
Study 15506589 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-cost multimodal psychosocial intervention
Number of subjects: 187
Study 15506589 — intervention group
Group type: COMPARATOR
Intervention: Treatment as usual (Control)
Number of subjects: 187
Study 10863139 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 400 mg single dose (Study A)
Number of subjects: 70
Study 10863139 — intervention group
Group type: EXPERIMENTAL
Intervention: Gabapentin 600 mg single dose (Study B)
Number of subjects: 70
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 2.5 microg
Number of subjects: 60
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 5.0 microg
Number of subjects: 60
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 7.5 microg
Number of subjects: 60
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 10.0 microg
Number of subjects: 60
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 12.5 microg
Number of subjects: 60
Study 9174303 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal sufentanil 15.0 microg
Number of subjects: 60
Study 1335539 — intervention group
Group type: EXPERIMENTAL
Intervention: Captopril (angiotensin-converting enzyme inhibitor)
Number of subjects: 0
Study 1335539 — intervention group
Group type: COMPARATOR
Intervention: Normal subjects (control group)
Number of subjects: 0
Study 3549877 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluoxetine treatment
Number of subjects: 49
Study 3549877 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49
Study 29421001 — intervention group
Group type: EXPERIMENTAL
Intervention: Prehospital ticagrelor treatment
Number of subjects: 1630
Study 29421001 — intervention group
Group type: EXPERIMENTAL
Intervention: Thrombus aspiration (TA)
Number of subjects: 1630
Study 29421001 — intervention group
Group type: COMPARATOR
Intervention: No thrombus aspiration (no-TA)
Number of subjects: 1630
Study 27390051 — intervention group
Group type: EXPERIMENTAL
Intervention: Paclitaxel liposome and capecitabine (PC group)
Number of subjects: 64
Study 27390051 — intervention group
Group type: COMPARATOR
Intervention: Docetaxel, cisplatin, and 5‐fluorouracil (DCF group, control group)
Number of subjects: 64
Study 27390051 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 64
Study 27390051 — intervention group
Group type: EXPERIMENTAL
Intervention: Experimental group
Number of subjects: 64
Study 25573705 — intervention group
Group type: EXPERIMENTAL
Intervention: High surgical ligature of spermatic vessels modified Palomo
Number of subjects: 0
Study 25573705 — intervention group
Group type: COMPARATOR
Intervention: Antegrade sclerotherapy according to Tauber
Number of subjects: 0
Study 22305833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration oxygen therapy (6 L/min via medium concentration mask)
Number of subjects: 136
Study 22305833 — intervention group
Group type: COMPARATOR
Intervention: Titrated oxygen therapy (to achieve oxygen saturation 93%-96%)
Number of subjects: 136
Study 22305833 — intervention group
Group type: EXPERIMENTAL
Intervention: High-concentration oxygen therapy
Number of subjects: 136
Study 20488431 — intervention group
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.0%
Number of subjects: 130
Study 20488431 — intervention group
Group type: EXPERIMENTAL
Intervention: bepotastine besilate ophthalmic solution 1.5%
Number of subjects: 130
Study 20488431 — intervention group
Group type: COMPARATOR
Intervention: placebo (0.0%)
Number of subjects: 130
Study 18515518 — intervention group
Group type: EXPERIMENTAL
Intervention: One E2 spray (1.53 mg E2, 90 microliter)
Number of subjects: 454
Study 18515518 — intervention group
Group type: EXPERIMENTAL
Intervention: Two E2 sprays (3.06 mg E2, 180 microliter)
Number of subjects: 454
Study 18515518 — intervention group
Group type: EXPERIMENTAL
Intervention: Three E2 sprays (4.59 mg E2, 270 microliter)
Number of subjects: 454
Study 18515518 — intervention group
Group type: COMPARATOR
Intervention: Placebo sprays
Number of subjects: 454
Study 15654152 — intervention group
Group type: EXPERIMENTAL
Intervention: Ventricular pacing mode
Number of subjects: 0
Study 15654152 — intervention group
Group type: EXPERIMENTAL
Intervention: Dual-chamber pacing mode
Number of subjects: 0
Study 15654152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing for heart failure in elderly patients
Number of subjects: 0
Study 15654152 — intervention group
Group type: EXPERIMENTAL
Intervention: Pacing combined with cardioverter‐defibrillator implantation
Number of subjects: 0
Study 11920905 — intervention group
Group type: EXPERIMENTAL
Intervention: Fast reporting by amnio-PCR (Group A)
Number of subjects: 60
Study 11920905 — intervention group
Group type: COMPARATOR
Intervention: Standard reporting (Group B)
Number of subjects: 60
Study 9704785 — intervention group
Group type: EXPERIMENTAL
Intervention: 140 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704
Study 9704785 — intervention group
Group type: EXPERIMENTAL
Intervention: 142 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704
Study 9704785 — intervention group
Group type: EXPERIMENTAL
Intervention: 141 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704
Study 9704785 — intervention group
Group type: EXPERIMENTAL
Intervention: 136 mg/dL cutoff value in oral glucose challenge test
Number of subjects: 704
Study 8527690 — intervention group
Group type: EXPERIMENTAL
Intervention: HI-6 (500 mg) with atropine sulphate (2 mg)
Number of subjects: 24
Study 1978503 — intervention group
Group type: EXPERIMENTAL
Intervention: D-phenylalanine (4.0 grams orally 30 minutes before acupuncture)
Number of subjects: 86
Study 1978503 — intervention group
Group type: EXPERIMENTAL
Intervention: D-phenylalanine (4.0 grams orally 30 minutes before acupuncture anesthesia)
Number of subjects: 86
Study 1978503 — intervention group
Group type: COMPARATOR
Intervention: D-phenylalanine (0.5 grams three times the day before treatment)
Number of subjects: 86
Study 631733 — intervention group
Group type: EXPERIMENTAL
Intervention: Phenformin 50 mg every 12 hours for 3 days before and during the fasts
Number of subjects: 8
Study 631733 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8
Study 31506859 — intervention group
Group type: EXPERIMENTAL
Intervention: Cognitive Processing Therapy for Posttraumatic Stress Disorder
Number of subjects: 0
Study 30144887 — intervention group
Group type: EXPERIMENTAL
Intervention: Top-D (Vitamin D3 gel made from proniosomal technology) applied daily on the skin, 1 g containing 5000 IU of vitamin D3
Number of subjects: 550
Study 30144887 — intervention group
Group type: COMPARATOR
Intervention: Aloe vera gel applied daily, 1 g
Number of subjects: 550
Study 26685814 — intervention group
Group type: EXPERIMENTAL
Intervention: HealthKick intervention
Number of subjects: 16
Study 26685814 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 16
Study 24585900 — intervention group
Group type: EXPERIMENTAL
Intervention: Modified St. Thomas' Hospital cardioplegic solution (group S)
Number of subjects: 90
Study 24585900 — intervention group
Group type: COMPARATOR
Intervention: Conventional glucose-insulin-potassium solution (group G)
Number of subjects: 90
Study 22732331 — intervention group
Group type: EXPERIMENTAL
Intervention: Lanthanum carbonate (LC)
Number of subjects: 13
Study 22732331 — intervention group
Group type: COMPARATOR
Intervention: Non-LC phosphorus binders (control)
Number of subjects: 13
Study 22732331 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 13
Study 20849601 — intervention group
Group type: EXPERIMENTAL
Intervention: Educational programme
Number of subjects: 207
Study 20849601 — intervention group
Group type: COMPARATOR
Intervention: Physical training programme
Number of subjects: 207
Study 17487874 — intervention group
Group type: EXPERIMENTAL
Intervention: Intensive pelvic floor exercises (PFE) starting 7 days after catheter removal for up to 1 year
Number of subjects: 107
Study 17487874 — intervention group
Group type: COMPARATOR
Intervention: Control group (no instructions)
Number of subjects: 107
Study 17487874 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual analogue scale (VAS) at 12 months
Number of subjects: 107
Study 17487874 — intervention group
Group type: EXPERIMENTAL
Intervention: Quality of Life (QoL) question at 12 months
Number of subjects: 107
Study 15843702 — intervention group
Group type: EXPERIMENTAL
Intervention: Benzylpenicillin and flucloxacillin combined
Number of subjects: 81
Study 15843702 — intervention group
Group type: COMPARATOR
Intervention: Flucloxacillin only
Number of subjects: 81
Study 12529796 — intervention group
Group type: EXPERIMENTAL
Intervention: Creatine monohydrate (Cr)
Number of subjects: 34
Study 12529796 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 34
Study 9829449 — intervention group
Group type: EXPERIMENTAL
Intervention: Losartan 50 mg once daily
Number of subjects: 100
Study 9829449 — intervention group
Group type: EXPERIMENTAL
Intervention: Lisinopril 20 mg once daily
Number of subjects: 100
Study 9829449 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100
Study 7862844 — intervention group
Group type: COMPARATOR
Intervention: 0.0 g/kg alcohol
Number of subjects: 20
Study 7862844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.3 g/kg alcohol
Number of subjects: 20
Study 7862844 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.6 g/kg alcohol
Number of subjects: 20
Study 2816793 — intervention group
Group type: EXPERIMENTAL
Intervention: 51 mmol NaCl/d
Number of subjects: 17
Study 2816793 — intervention group
Group type: EXPERIMENTAL
Intervention: 102 mmol NaCl/d
Number of subjects: 17
Study 2816793 — intervention group
Group type: COMPARATOR
Intervention: Control (usual diet without supplementation)
Number of subjects: 17
Study 1104303 — intervention group
Group type: EXPERIMENTAL
Intervention: etofibrate
Number of subjects: 21
Study 1104303 — intervention group
Group type: EXPERIMENTAL
Intervention: clofibrate
Number of subjects: 21
Study 1104303 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 21
Study 463982 — intervention group
Group type: EXPERIMENTAL
Intervention: Pelvic plus abdominopelvic irradiation (P + AB)
Number of subjects: 190
Study 463982 — intervention group
Group type: COMPARATOR
Intervention: Pelvic irradiation alone or followed by adjuvant daily chlorambucil therapy
Number of subjects: 190
Study 463982 — intervention group
Group type: EXPERIMENTAL
Intervention: Chlorambucil added to pelvic irradiation
Number of subjects: 190
Study 28398129 — intervention group
Group type: EXPERIMENTAL
Intervention: Tai Chi: Moving for Better Balance (12-week program)
Number of subjects: 131
Study 30283182 — intervention group
Group type: EXPERIMENTAL
Intervention: Lidocaine 2 mg/kg/h with a maximum of 200 mg/h starting at induction of anesthesia until the end of surgery
Number of subjects: 80
Study 30283182 — intervention group
Group type: COMPARATOR
Intervention: Magnesium sulfate 50 mg/kg iv bolus in 100ml saline over 10 min followed by infusion of 15 mg/kg/h until the end of surgery
Number of subjects: 80
Study 26633571 — intervention group
Group type: EXPERIMENTAL
Intervention: Genomic Grade assay
Number of subjects: 883
Study 26633571 — intervention group
Group type: COMPARATOR
Intervention: Histological grade
Number of subjects: 883
Study 26633571 — intervention group
Group type: EXPERIMENTAL
Intervention: GG equivocal patients
Number of subjects: 883
Study 26633571 — intervention group
Group type: EXPERIMENTAL
Intervention: GG3 patients
Number of subjects: 883
Study 26633571 — intervention group
Group type: EXPERIMENTAL
Intervention: Ki67
Number of subjects: 883